Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ifinatamab Deruxtecan (I-DXd) + Atezolizumab +/- Carboplatin in 1L ES-SCLC (IDeate-Lung03)
NCT06362252Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2024
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of ifinatamab deruxtecan in small cell lung cancer (SCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Jul 2024; status: recruiting.
02
Drugs
ifinatamab deruxtecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06362252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06362252.